Mylan NV (MYL)

44.50
2.60 6.30
NASDAQ : Health Care
Prev Close 41.85
Open 44.34
Day Low/High 44.10 / 45.87
52 Wk Low/High 37.59 / 67.34
Volume 11.76M
Avg Volume 5.34M
Exchange NASDAQ
Shares Outstanding 535.11M
Market Cap 22.71B
EPS 1.80
P/E Ratio 84.88
Div & Yield N.A. (N.A)

Latest News

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Impax Laboratories, Clearside Biomedical and Mylan were among the biotech stock movers in premarket trading Wednesday.

Stock Futures Higher as Chances Rise of a Rate Hike in March

Stock Futures Higher as Chances Rise of a Rate Hike in March

Stock futures suggest Wall Street would get back to its record-breaking ways on Wednesday as chances rose of a return to normal U.S. monetary policy sooner rather than later.

Mylan Stock Spikes on Earnings Beat

Mylan Stock Spikes on Earnings Beat

Mylan topped bottom line estimates by 15 cents.

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.

We Might See a Pullback in Bonds Sometime This Week

In one scenario, we crack these levels and then come back and retest on the pullback.

U.S. FDA Accepts Biologics License Application (BLA) For Mylan And Biocon's Proposed Biosimilar Pegfilgrastim For Review

U.S. FDA Accepts Biologics License Application (BLA) For Mylan And Biocon's Proposed Biosimilar Pegfilgrastim For Review

Second Successful BLA Filing of the Partnership in the U.S.

How Kaleo Pharma Prices Its EpiPen Competitor

How Kaleo Pharma Prices Its EpiPen Competitor

Kaleo's EpiPen compeitor the Auvi-Q was released today.

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.

Mylan Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Skyworks Solutions

Mylan Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Skyworks Solutions

The most recent short interest data has been released for the 01/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

CVS Remains Unsure About the Future of Obamacare, CEO Says

CVS Remains Unsure About the Future of Obamacare, CEO Says

The company had a mixed fourth quarter.

Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns

Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns

GlaxoSmithKline beat analysts' expectations for fourth-quarter sales and earnings Wednesday but warned of a significant hit this year from anticipated generic competition to its Advair asthma treatment.

Despite Settling Decade-Long Suit, Mylan Shares Fall

Despite Settling Decade-Long Suit, Mylan Shares Fall

Mylan settled a pay-for-delay lawsuit over its narcolepsy drug, but its share prices are falling.

There Is Nothing Generic About the Basing Action on Mylan

There Is Nothing Generic About the Basing Action on Mylan

Prices look set to test key resistance, and this time should see a breakout to the upside.

House Panel to Take Up Trump's Call to Speed FDA Approvals

House Panel to Take Up Trump's Call to Speed FDA Approvals

Generics for drugs facing shortages or having few manufacturers is bill's focus.

Mylan Benefits From Teva's Multiple Sclerosis Patent Dispute Woes

Mylan Benefits From Teva's Multiple Sclerosis Patent Dispute Woes

Mylan's shares rose after Teva's claims of patent infringement were rejected, despite the announcement that the FTC is investigating the drugmaker for antitrust violations.

Mylan's Shares Rise Despite FTC Investigation

Mylan's Shares Rise Despite FTC Investigation

The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Mylan, Momenta Pharmaceuticals and Seres Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

The autoinjector will be free for insured patients and those whose annual income is less than $100,000.

Biotech Premarket Movers: SGMO, IPXL, PTLA

Biotech Premarket Movers: SGMO, IPXL, PTLA

Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

The drug maker's shares have fallen 6.2% since Wednesday's market open.

Insulin Drug Offers Hope for MannKind

Insulin Drug Offers Hope for MannKind

The stock has taken a beating, but users of Afrezza are loyal to the drug.

Patent Victory Secures Lilly Hold on Cancer Drug Until 2022

Patent Victory Secures Lilly Hold on Cancer Drug Until 2022

An appeals court in Indiana upheld Eli Lilly's patent regarding Alimta, a major cancer drug for Lilly, keeping Teva and other generic drug specialists at bay.

CVS Is the Latest to Rock Mylan's EpiPen Empire

CVS Is the Latest to Rock Mylan's EpiPen Empire

The price of EpiPens has surged about 25% annually since 2007.

Cigna Will No Longer Cover Mylan's EpiPen

Cigna Will No Longer Cover Mylan's EpiPen

Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.